Browsing Tag
cell therapy
19 posts
Cynata Therapeutics (ASX: CYP) completes Phase 2 enrolment for CYP-001 as investors refocus on June 2026 data inflection
Cynata Therapeutics completes Phase 2 enrolment for CYP-001, shifting focus to June 2026 data. Read what this means for strategy, risk, and valuation.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
Biorep achieves first successful independent PRISM system use in islet isolation
Biorep’s PRISM system achieves first independent islet isolation milestone at SNBTS. Discover how it’s shaping the future of lab automation.
Will Enlivex’s macrophage therapy redefine osteoarthritis care in seniors?
Enlivex posts 6-month knee osteoarthritis trial success with Allocetra, signaling a new era in age-targeted cell therapy. See what comes next.
Breakthrough allogeneic immunotherapy from Lunai Bioworks eliminates pancreatic tumors in preclinical study
Find out how Lunai Bioworks’ engineered dendritic-cell therapy achieved complete regression of pancreatic cancer in preclinical models and what it means for solid-tumor immunotherapy.
Is Ernexa Therapeutics (NASDAQ: ERNA) turning into the next small‑cap biotech breakout?
Is Ernexa Therapeutics (NASDAQ: ERNA) the next small-cap biotech breakout? Learn how its iMSC platform and Cellipont partnership could change its trajectory.
Ernexa Therapeutics (NASDAQ: ERNA) surges 68% after Cellipont deal to advance ovarian cancer cell therapy ERNA‑101
Ernexa Therapeutics stock jumps 68% after partnering with Cellipont to manufacture its ovarian cancer cell therapy ERNA-101. Learn what’s driving investor interest.
How Northwest Biotherapeutics’ acquisition of Advent BioServices may reshape its cell therapy strategy
Northwest Biotherapeutics acquires Advent BioServices to scale DCVax production and integrate UK manufacturing. Find out what this means for its immunotherapy pipeline.
Bristol Myers Squibb’s CD19 NEX-T therapy shows 94% off immunosuppressants in early Phase 1 results
Bristol Myers Squibb’s CAR T cell therapy shows early promise in autoimmune disorders. Find out what the data means for the stock and the wider market.
Genenta Science partners with Anemocyte to unlock scalable LVV plasmid DNA supply for global cell and gene therapy developers
Find out how Genenta Science and Anemocyte are scaling off-the-shelf LVV plasmid DNA to revolutionize global gene and cell therapy manufacturing.